Report: Takeda adopts value-based pricing for Crohn’s stem cell therapy in Europe
Source: http://bit.ly/2INQ1wy
Nikkei Asian Review reported that the company would cover some or all the cost of the therapy, Alofisel, which won EMA approval last year, if it did not provide benefit. The UK’s NICE has declined to recommend it, citing modest benefit in a clinical trial.
Source: http://bit.ly/2INQ1wy
0 Comments